• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Gains 100 Points; McCormick Posts Upbeat Results

    3/26/24 12:08:08 PM ET
    $APCX
    $CDLX
    $GDS
    $MESO
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Technology
    Get the next $APCX alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday.

    The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36.

    Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1

     

    Leading and Lagging Sectors

     

    Consumer discretionary shares jumped by 0.8% on Monday.

    In trading on Monday, energy shares fell by 0.6%.

     

    Top Headline

     

    McCormick & Co Inc (NYSE:MKC) reported better-than-expected first-quarter financial results.

    McCormick reported first-quarter FY24 sales growth of 3% year-on-year to $1.60 billion, beating the analyst consensus estimate of $1.56 billion. Adjusted EPS of 63 cents beat the consensus of 58 cents.

     

    Equities Trading UP

     

    Stoke Therapeutics, Inc. (NASDAQ:STOK) shares shot up 73% to $11.25 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.

    Shares of Mesoblast Ltd (NASDAQ:MESO) got a boost, surging 36% to $3.00 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.

    OpGen, Inc. (NASDAQ:OPGN) shares were also up, gaining 37% to $0.65 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million.

     

    Equities Trading DOWN

     

    Cardlytics Inc (NASDAQ:CDLX) shares dropped 31% to $13.93 after the company announced a $150 million proposed convertible senior notes offering.

    Shares of GDS Holdings Ltd - ADR (NASDAQ:GDS) were down 19% to $6.76 after the company reported fourth-quarter results, disclosed equity raise and new CEO for its international business.

    AppTech Payments Corp. (NASDAQ:APCX) was down, falling 39% to $81.62 after the company priced its 2 million share offering at $1 per share.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 0.4% to $81.62 while gold traded up 0.3% at $2,183.00.

    Silver traded down 0.7% to $24.71 on Monday, while copper fell 0.5% to $3.9975.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.16%, London’s FTSE 100 rose 0.11% while Spain’s IBEX 35 Index rose 0.31% The German DAX rose 0.74% French CAC 40 rose 0.35% while Italy’s FTSE MIB Index rose 0.22%.

    The GfK Consumer Climate Indicator for Germany rose to -27.4 heading into April compared to a revised reading of -28.8 in the prior period. Spanish economy grew 0.6% in the fourth quarter, compared to a 0.4% increase in the prior period.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 falling 0.04%, Hong Kong’s Hang Seng Index gaining 0.88%, China’s Shanghai Composite Index gaining 0.17% and India’s S&P BSE Sensex falling 0.50%.

    Hong Kong’s trade deficit narrowed to $41.7 billion in February versus a $45.4 billion gap recorded in the year-ago period.

     

    Economics

     

    U.S. durable goods orders increased by 1.4% month-over-month in February versus a revised 6.9% decline in January.

    The S&P CoreLogic Case-Shiller 20-city home price index increased by 6.6% year-over-year in January compared to a 6.2% gain in the prior month.

    The FHFA house price index fell by 0.1% in January.

    The Dallas Fed general business activity index for Texas' service sector fell to a reading of -5.5 in March from -3.9 in February.

    Now Read This: How To Earn $500 A Month From Micron Technology Stock After Last Week's Strong Earnings

    Get the next $APCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APCX
    $CDLX
    $GDS
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    McCormick & Company Incorporated
    $MKC
    12/15/2025$75.00Hold → Buy
    Deutsche Bank
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    GDS Holdings Limited
    $GDS
    11/6/2025Outperform
    Macquarie
    McCormick & Company Incorporated
    $MKC
    8/20/2025$83.00Neutral → Overweight
    Analyst
    GDS Holdings Limited
    $GDS
    8/12/2025$48.00Sector Perform → Outperform
    RBC Capital Mkts
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    More analyst ratings

    $APCX
    $CDLX
    $GDS
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    McCormick upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded McCormick from Hold to Buy and set a new price target of $75.00

    12/15/25 9:08:18 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    $APCX
    $CDLX
    $GDS
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Sto

    2/4/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GDS Announces Private Placement of US$300 Million convertible preferred shares to A Chinese Institutional Investor

    SHANGHAI, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:GDS, HKEX: 9698)), a leading developer and operator of high-performance data centers in China, today announced a private placement of US$300 million of Series B convertible preferred shares (the "convertible preferred shares") to Huatai Capital Investment Limited, a Chinese institutional investor (the "Private Placement"). GDS will use the proceeds from the private placement to fund expansion of its data center capacity and for general corporate purposes. The convertible preferred shares include the following key terms: During the first six years from their issuance da

    1/30/26 8:40:00 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    Ryoncil® Net Revenues Increase for the Quarter to US$30M

    NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. "This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil®," said Mesoblast Chief Executive Dr. Silviu Itescu. FINANCIAL HIGHLIGHTS FOR QUARTER ENDED DECEMBER 31, 20251 Ryoncil® gross sales for the quarter were US$35 million, a 60

    1/28/26 6:54:06 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APCX
    $CDLX
    $GDS
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President, Gen Counsel Schwartz Jeffery D exercised 10,000 units of Common Stock - Voting at a strike of $49.96 and covered exercise/tax liability with 8,720 units of Common Stock - Voting, increasing direct ownership by 1% to 91,308 units (SEC Form 4)

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    2/5/26 1:20:30 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Director Tapiero Jacques exercised 5,000 units of Common Stock - Voting at a strike of $49.96 and sold $319,250 worth of Common Stock - Voting (5,000 units at $63.85), increasing direct ownership by 0.00% to 31,596 units (SEC Form 4)

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    2/4/26 2:22:22 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Chief Human Relations Officer Piper Sarah acquired $1,054 worth of Common Stock - Voting (16 units at $67.16), increasing direct ownership by 0.16% to 9,631 units (SEC Form 4)

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    2/4/26 11:11:53 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    $APCX
    $CDLX
    $GDS
    $MESO
    SEC Filings

    View All

    SEC Form DEF 14A filed by OpGen Inc.

    DEF 14A - OPGEN INC (0001293818) (Filer)

    2/6/26 1:05:05 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form 6-K filed by GDS Holdings Limited

    6-K - GDS Holdings Ltd (0001526125) (Filer)

    2/6/26 8:43:35 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    SEC Form 6-K filed by GDS Holdings Limited

    6-K - GDS Holdings Ltd (0001526125) (Filer)

    2/6/26 8:03:49 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    $APCX
    $CDLX
    $GDS
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lord Albert L bought $52,132 worth of shares (120,000 units at $0.43), increasing direct ownership by 4% to 3,016,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    12/4/25 7:22:39 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $23,347 worth of shares (57,500 units at $0.41), increasing direct ownership by 2% to 2,896,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    11/28/25 5:11:59 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $APCX
    $CDLX
    $GDS
    $MESO
    Financials

    Live finance-specific insights

    View All

    GDS Announces Private Placement of US$300 Million convertible preferred shares to A Chinese Institutional Investor

    SHANGHAI, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:GDS, HKEX: 9698)), a leading developer and operator of high-performance data centers in China, today announced a private placement of US$300 million of Series B convertible preferred shares (the "convertible preferred shares") to Huatai Capital Investment Limited, a Chinese institutional investor (the "Private Placement"). GDS will use the proceeds from the private placement to fund expansion of its data center capacity and for general corporate purposes. The convertible preferred shares include the following key terms: During the first six years from their issuance da

    1/30/26 8:40:00 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    McCORMICK REPORTS STRONG 2025 FINANCIAL RESULTS AND PROVIDES 2026 OUTLOOK

    HUNT VALLEY, Md., Jan. 22, 2026 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today reported financial results for the fourth quarter and fiscal year ended November 30, 2025 and provided its financial outlook for fiscal year 2026. Net sales increased 3% in the fourth quarter from the year-ago period and included a 1% favorable impact from currency. Organic sales grew 2% compared to the year-ago period. Earnings per share was $0.84 in the fourth quarter compared to $0.80 in the year-ago period. Adjusted earnings per share was $0.86 compared to $0.80 in the year-ago period. Operating income was $311 million in the fourth quarter compared to $306 mill

    1/22/26 6:30:00 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    McCormick Completes Acquisition of Controlling Interest in McCormick de Mexico

    HUNT VALLEY, Md., Jan. 2, 2026 /PRNewswire/ -- McCormick & Company Inc. (NYSE: MKC) (the "Company"), a global leader in flavor, today announced that it has completed the acquisition of an additional 25% ownership interest in McCormick de Mexico from Grupo Herdez, increasing its ownership to 75%. The Company previously announced its agreement to expand ownership in McCormick de Mexico on August 21, 2025. The expanded ownership of McCormick de Mexico, a joint venture formed in 1947 with Grupo Herdez, strengthens McCormick's global flavor leadership, creates opportunities for further growth in the attractive Mexican market and provides a strategic platform for further expansion in Latin Americ

    1/2/26 4:00:00 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    $APCX
    $CDLX
    $GDS
    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    McCormick Appoints Gavin Hattersley and Rick Dierker to Board of Directors

    HUNT VALLEY, Md., Jan. 21, 2026 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today announced that Gavin Hattersley, retired President and Chief Executive Officer of Molson Coors Beverage Company, and Rick Dierker, President and Chief Executive Officer of Church & Dwight Co., Inc., have been appointed to McCormick's Board of Directors effective February 1, 2026. Mr. Hattersley brings more than 35 years of leadership experience spanning the global consumer packaged goods and beverage industries. Most recently, he served as President an

    1/21/26 4:15:00 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    GDS Announces Results of Annual General Meeting of Shareholders

    SHANGHAI, China, June 26, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:GDS, HKEX: 9698)), a leading developer and operator of high-performance data centers in China, today announced that it held its Annual General Meeting of Shareholders ("2025 AGM") on June 26, 2025. Each of the resolutions submitted to the shareholders for approval at the 2025 AGM has been approved. Specifically, the shareholders of the Company passed ordinary resolutions approving: Re-election of Mr. William Wei Huang as a director of the Company;Re-election of Ms. Bin Yu as a director of the Company;Re-election of Mr. Zulkifli Baharudin as a director of the Company;Co

    6/26/25 7:00:07 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    $APCX
    $CDLX
    $GDS
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care